Metformin inhibits mTORC1 even in cells lacking AMPK or TSC1/TSC2, and the effect requires the Rag GTPases instead. Together with Foretz 2010 this places a large part of metformin's action outside the AMPK axis it is usually credited to.
Tier D because it is mechanistic or in-vitro work (model: Mammalian cells (AMPK-null and TSC1/2-null)), not a whole-organism health-outcome study; tier describes study design, not quality -- this is often exactly where causal biology gets established.
| Evidence tier | D Mechanistic / in vitro / review |
| Study type | 5 - Mechanistic / In Vitro |
| Model system | Mammalian cells (AMPK-null and TSC1/2-null) |
| Journal | Cell Metabolism |
| Year | 2010 |
| Peer reviewed | Yes |
| Record last updated | 2026-07-29 |
| Source | DOI 10.1016/j.cmet.2010.03.014 · PMID 20444419 |
| Target | Metformin -> Rag GTPases -> mTORC1 (AMPK-independent) |
| Model | Mammalian cells |
| Effect | Metformin inhibits mTORC1 without AMPK or TSC1/2, in a Rag GTPase-dependent manner |
Barton, O. (2026). Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner — evidence-graded record KAL2010. In Oliver's mTOR Atlas. https://mtor-atlas.org/study/KAL2010/ · Dataset DOI 10.5281/zenodo.22059963
@misc{atlas_KAL2010,
author = {Barton, Oliver},
title = {{Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner} --- evidence-graded record KAL2010},
howpublished = {Oliver's mTOR Atlas},
year = {2026},
url = {https://mtor-atlas.org/study/KAL2010/},
note = {Dataset DOI: 10.5281/zenodo.22059963}
}